Rhumbline Advisers Voyager Therapeutics, Inc. Transaction History

Rhumbline Advisers

$113 Billion
Q2 2025

A detailed history of Rhumbline Advisers transactions in Voyager Therapeutics, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 68,287 shares of VYGR stock, worth $331,191. This represents 0.0% of its overall portfolio holdings.

Number of Shares

68,287

Previous 67,977 0.46%

Holding current value

$331,191

Previous $229,000 7.42%

% of portfolio

0.0%

Previous 0.0%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 12, 2025	BUY	$2.73 - $3.64 $846 - $1,128	310 Added 0.46%	68,287 $212,000
Q1 2025 Apr 08, 2025	SELL	$3.38 - $6.04 $11,897 - $21,260	-3,520 Reduced 4.92%	67,977 $248,000
Q4 2024 May 29, 2025	BUY	$5.27 - $8.07 $18,550 - $28,406	3,520 Added 5.18%	71,497 $405,000
Q4 2024 Jan 30, 2025	BUY	$5.27 - $8.07 $12,405 - $18,996	2,354 Added 3.4%	71,497 $405,000
Q3 2024 Nov 12, 2024	SELL	$5.77 - $9.27 $19,144 - $30,757	-3,318 Reduced 4.58%	69,143 $404,000
Q2 2024 Aug 01, 2024	BUY	$7.42 - $10.54 $193,023 - $274,187	26,014 Added 56.01%	72,461 $573,000
Q1 2024 May 09, 2024	BUY	$7.15 - $10.84 $26,533 - $40,227	3,711 Added 8.68%	46,447 $432,000
Q4 2023 Feb 08, 2024	SELL	$6.28 - $8.81 $1,909 - $2,678	-304 Reduced 0.71%	42,736 $360,000
Q3 2023 Nov 09, 2023	BUY	$7.55 - $11.25 $12,298 - $18,326	1,629 Added 3.93%	43,040 $333,000
Q2 2023 Aug 08, 2023	BUY	$6.94 - $13.99 $287,392 - $579,339	41,411 New	41,411 $474,000
Q2 2021 Aug 05, 2021	SELL	$3.94 - $5.44 $133,439 - $184,241	-33,868 Closed	0 $0
Q1 2021 May 06, 2021	SELL	$4.61 - $9.04 $5,993 - $11,751	-1,300 Reduced 3.7%	33,868 $160,000
Q4 2020 Feb 10, 2021	BUY	$7.15 - $12.28 $22,165 - $38,068	3,100 Added 9.67%	35,168 $251,000
Q3 2020 Nov 12, 2020	SELL	$10.01 - $13.75 $49,499 - $67,993	-4,945 Reduced 13.36%	32,068 $342,000
Q2 2020 Aug 13, 2020	BUY	$8.05 - $14.21 $27,820 - $49,109	3,456 Added 10.3%	37,013 $467,000
Q1 2020 May 06, 2020	SELL	$6.8 - $14.66 $6,963 - $15,011	-1,024 Reduced 2.96%	33,557 $307,000
Q4 2019 Feb 05, 2020	BUY	$12.82 - $16.85 $27,575 - $36,244	2,151 Added 6.63%	34,581 $482,000
Q3 2019 Oct 23, 2019	BUY	$16.31 - $28.29 $1,141 - $1,980	70 Added 0.22%	32,430 $558,000
Q2 2019 Aug 14, 2019	BUY	$19.18 - $27.88 $91,411 - $132,876	4,766 Added 17.27%	32,360 $881,000
Q1 2019 May 01, 2019	SELL	$8.0 - $19.66 $3,160 - $7,765	-395 Reduced 1.41%	27,594 $528,000
Q4 2018 Jan 31, 2019	BUY	$8.59 - $18.05 $78,048 - $164,002	9,086 Added 48.07%	27,989 $263,000
Q3 2018 Nov 07, 2018	SELL	$17.11 - $21.74 $23,184 - $29,457	-1,355 Reduced 6.69%	18,903 $358,000
Q2 2018 Aug 06, 2018	BUY	$16.76 - $23.92 $52,492 - $74,917	3,132 Added 18.29%	20,258 $396,000
Q1 2018 May 02, 2018	BUY	$16.16 - $31.31 $40,286 - $78,055	2,493 Added 17.04%	17,126 $322,000
Q4 2017 Feb 09, 2018	SELL	$12.26 - $25.88 $19,591 - $41,356	-1,598 Reduced 9.85%	14,633 $243,000
Q3 2017 Nov 06, 2017	BUY	$8.37 - $20.59 $135,853 - $334,196	16,231	16,231 $334,000

Others Institutions Holding VYGR

# of Institutions

120

Shares Held

32.8M

Call Options Held

32.9K

Put Options Held

22.7K

View Full List

About Voyager Therapeutics, Inc.

Ticker VYGR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,647,600
Market Cap $187M
Description
Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyo...

More about VYGR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Account

Rhumbline Advisers Voyager Therapeutics, Inc. Transaction History